Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis and Bristol-Myers Squibb have received European approval for dual antiplatelet combination tablet DuoPlavin/DuoCover (clopidogrel 75mg and acetylsalicylic acid 100mg or 75mg) from the European Commission.
Subscribe to our email newsletter
DuoPlavin/DuoCover is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA). It is a fixed dose combination medicinal product for continuation of therapy in non-ST segment elevation acute coronary syndrome including patients undergoing a stent placement following percutaneous coronary intervention.
DuoPlavin/DuoCover is also indicated for the treatment of ST-segment elevation acute myocardial infarction in medically treated patients eligible for thrombolytic therapy.
Both the parties said that the new formulation of DuoPlavin/DuoCover carrying both these antiplatelets in one single tablet contributes to reducing daily pill burden for patients.